CoChat

Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses

Open access
Rolan, Paul, Gibbons, Jacqueline A., He, Lin, Chang, Eppie, Jones, Drew, Gross, Matthew I., Davidson, Jennifer Bahr, Sanftner, Laura M., Johnson, Kirk W. · 2008 · British Journal of Clinical Pharmacology
Cited by 70

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Ibudilast is an oral drug approved in Asia for asthma. • Tolerability of 10‐mg regimens has been described previously. • Published pharmacokinetics (PK) are limited: single or 7‐day repeat oral administration of 10 mg in healthy male Asian volunteers. WHAT THIS STUDY ADDS • Safety/tolerability and PK of a single 30‐mg dose and a 30‐mg twice daily (b.i.d.) 2‐week regimen in male and female healthy volunteers. • Higher‐dose regimens are relevant for testing in new neurological indications. • LC‐MS/MS analytics for quantification of plasma and urine levels of ibudilast parent and its primary metabolite (6,7‐dihydrodiol‐ibudilast). AIMS: To investigate the safety, tolerability and pharmacokinetics (PK) of ibudilast after a single‐dose and a multiple‐dose regimen. METHODS: Healthy adult male (n = 9) and female (n = 9) volunteers were evaluated over a 17‐day stay in a Phase 1 unit. Subjects were randomized 1 : 3 to either oral placebo or ibudilast at 30‐mg single administration followed by 14 days of 30 mg b.i.d. Complete safety analyses were performed and, for PK, plasma and urine samples were analysed for ibudilast and its major metabolite. RESULTS: Ibudilast was generally well tolerated. No serious adverse events occurred. Treatment‐related adverse events included hyperhidrosis, headache and nausea. Two subjects discontinued after a few days at 30 mg b.i.d. because of vomiting. Although samples sizes were too small to rule out a sex difference, PK were similar in men and women. The mean half‐life for ibudilast was 19 h and median Tmax was 4–6 h. Mean (SD) steady‐state plasma Cmax and AUC 0–24 were 60 (25) ng ml−1 and 1004 (303) ng h ml−1, respectively. Plasma levels of 6,7‐ dihydrodiol‐ibudilast were approximately 30% of the parent. CONCLUSIONS: Ibudilast is generally well tolerated in healthy adults when given as a single oral dose of 30 mg followed by 30 mg b.i.d. (60 mg day−1) for 14 days. Plasma PK reached steady state within 2 days of starting the b.i.d. regimen. Exposure to ibudilast was achieved of a magnitude comparable to that associated with efficacy in rat chronic pain models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2008.03270.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 70

Metadata

Authors
Rolan, P., Gibbons, J. A., He, L., Chang, E., Jones, D., Gross, M. I., Davidson, J. B., Sanftner, L. M., & Johnson, K. W.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2008-11-20
Volume
66
Issue
6
Pages
792-801
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2076375479
Cited by
70
References
1
FWCI
4.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. https://app.cochat.ai/papers/10.1111/j.1365-2125.2008.03270.x
The paper
Rolan, P., Gibbons, J. A., He, L., Chang, E., Jones, D., Gross, M. I., Davidson, J. B., Sanftner, L. M., & Johnson, K. W. (2008). Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2008.03270.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.